Our results showed that PE could efficiently install therapeutic corrections in a targeted and precise manner, suggesting that future PE3-induced beta-thalassemia therapy could be used to modify the BCL11A enhancer and induce precise corrections at each mutation site. The gene discussed is BCL11A; the disease is Beta-thalassemia.